47 : 235248 Pettegrew JW, Panchalingam K, Klunk WE, McClure RJ, Muenz LR
Lewis JE, Kemp ML
The combination of all four pathways should theoretically produce earlier onset of appetite suppression, more sustained fullness between meals, increased resting energy expenditure from the glucagon component, and a reduced tendency toward the metabolic adaptation that commonly causes weight loss plateaus on single-agent therapy
An intradermal test dose is recommended before administration in patients suspected of being sensitive to the drug
People with past or present history of anxiety, depression, or mood disorders should be cautious and see a doctor if issues arise
Related article: TSA: Traveling with Injectable Medications, Needles, and Syringes